We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

56 hedge funds and large institutions have $52.6M invested in Cartesian Therapeutics in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 11

88% more capital invested

Capital invested by funds: $28M → $52.6M (+$24.6M)

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

4% more funds holding

Funds holding: 54 → 56 (+2)

0.1% more ownership

Funds ownership: 1.56% → 1.66% (+0.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

70% less call options, than puts

Call options by funds: $9K | Put options by funds: $30K

Holders
56
Holders Change
+2
Holders Change %
+3.7%
% of All Funds
1.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
27
Reduced
11
Closed
9
Calls
$9K
Puts
$30K
Net Calls
-$21K
Net Calls Change
-$12K

Top Buyers

Rank Fund Capital Flow
1
Man Group
Man Group
United Kingdom
+$6.58M
2
WA
Wasatch Advisors
Utah
+$5.94M
3
AG
Artal Group
Luxembourg
+$3.17M
4
O
OrbiMed
New York
+$2.75M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.61M

Top Sellers

Rank Fund Capital Flow
1
KCM
Kennedy Capital Management
Missouri
-$1.6M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1.04M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$658K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$221K
5
Deutsche Bank
Deutsche Bank
Germany
-$179K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
51
Ameritas Investment Partners
Nebraska
$2K – – –
FIA
52
FNY Investment Advisers
New York
$2K +$2.09K +33 New
CG
53
Cutler Group
California
$1K -$2.15K -34 -63%
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
$1K +$634 +10 +125%
KCM
55
Kennedy Capital Management
Missouri
– -$1.6M -20,032 Closed
Jacobs Levy Equity Management
56
Jacobs Levy Equity Management
New Jersey
– -$221K -2,775 Closed
ARTA
57
A.R.T. Advisors
New York
– -$105K -1,311 Closed
Citadel Advisors
58
Citadel Advisors
Florida
– -$59K -739 Closed
CPP
59
Crow Point Partners
Massachusetts
– -$50K -573 Closed
JG
60
Jefferies Group
New York
– -$41K -514 Closed
Susquehanna International Group
61
Susquehanna International Group
Pennsylvania
– -$34K -423 Closed
TRCT
62
Tower Research Capital (TRC)
New York
– -$34K -417 Closed
UBS Group
63
UBS Group
Switzerland
– -$22.9K -361 -99%
Millennium Management
64
Millennium Management
New York
– -$28K -350 Closed
SEI Investments
65
SEI Investments
Pennsylvania
– +$63 +1 New
1 2
3

RNAC Hedge Fund Activity: Q1 2019 in Review

56 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2019, worth a combined $52.6M — up 88% from $28M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new RNAC positions and 9 closed out — a net gain of 2 holders — while 27 added to existing stakes and 11 trimmed.

The largest buyer was Man Group, adding an estimated $6.58M. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $1.6M sold.

  • 56 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2019, up from 54 in Q4 2018.
  • Funds reported $52.6M of Cartesian Therapeutics stock for Q1 2019, up 88% quarter-over-quarter.
  • 11 funds opened new Cartesian Therapeutics positions in Q1 2019 and 9 closed out, a net change of +2 holders.
  • The largest Cartesian Therapeutics buyer in Q1 2019 was Man Group, an estimated $6.58M added.
  • The largest Cartesian Therapeutics seller in Q1 2019 was Kennedy Capital Management, an estimated $1.6M sold.

Based on aggregated 13F filings for Q1 2019.